| |
Original Artikel |
Datum |
Titel |
Autoren Max. 6 Autoren |
| 1 |
[GO] |
2026―Mai―18 |
Repurposed Medicines for Viruses With Epidemic or Pandemic Potential: A Horizon Scan |
Sola Akinbolade, Rhiannon Potter, Alex Inskip, Jane Nesworthy, Kirsti Brock, Gill Norman |
| 2 |
[GO] |
2025―Mai―02 |
Supporting Pediatric RSV Clinical Trials Through Close Epidemiological Surveillance During the SARS-CoV-2 Pandemic |
Rennie Joshi, Georges J. Nahhas, Carmen S. Arriola, Patricia Saddier, Andrea Guerra |
| 3 |
[GO] |
2024―Nov―07 |
Favipiravir pharmacokinetics in Thai adults with mild COVID-19: A sub-study of interpatient variability and ethnic differences in exposure |
Ing-orn Prasanchaimontri, Weerawat Manosuthi, Henry Pertinez, Andrew Owen, Suvimol Niyomnaitham, Rujipas Sirijatuphat, Lantharita Charoenpong, Tim R. Cressey, Katherine Copeland, Phongpan Mokmued, Kulkanya Chokephaibulkit |
| 4 |
[GO] |
2024―Okt―01 |
Effect of vitamin D supplementation on clinical outcomes in adult patients with COVID-19: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials |
Zohreh-al-sadat Ghoreshi, Javad Charostad, Nasir Arefinia, Mohsen Nakhaie, Mohammad Rezaei Zadeh Rukerd, Faranak Salajegheh |
| 5 |
[GO] |
2024―Sep―12 |
An improvement of the safety profile of SARS-CoV-2 vaccines is desirable |
Josef Finsterer |
| 6 |
[GO] |
2024―Jun―13 |
Long-lasting, biochemically modified mRNA, and its frameshifted recombinant spike proteins in human tissues and circulation after COVID-19 vaccination |
László G. Boros, Anthony M. Kyriakopoulos, Carlo Brogna, Marina Piscopo, Peter A. McCullough, Stephanie Seneff |
| 7 |
[GO] |
2024―Jun―12 |
Incidence and management of the main serious adverse events reported after COVID-19 vaccination |
Teresa Padilla-Flores, Alicia Sampieri, Luis Vaca |
| 8 |
[GO] |
2024―Apr―04 |
Ursodeoxycholic acid may protect from severe acute respiratory syndrome coronavirus 2 Omicron variant by reducing angiotensin-converting enzyme 2 |
Kyungmin Lee, Yujeong Na, Minjin Kim, Dongjin Lee, Jongseo Choi, Gwanyoung Kim, Min-Soo Kim |
| 9 |
[GO] |
2023―Jun―03 |
Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial |
Noémie Mercier, Drifa Belhadi, Aline DeChanet, Christelle Delmas, Juliette Saillard, Marina Dumousseaux, Soizic Le Mestre, Claire Fougerou-Leurent, Assia Ferrane, Charles Burdet, Hélène Espérou, Florence Ader, Maya Hites, Nathan Peiffer-Smadja, Julien Poissy, Claire Andrejak, José Artur Paiva, Evelina Tacconelli, Thérèse Staub, Richard Greil, Dominique Costagliola, France Mentre, Yazdan Yazdanpanah, Alpha Diallo |
| 10 |
[GO] |
2023―Mai―03 |
The influence of
SARS-CoV
-2 infection on expression of drug-metabolizing enzymes and transporters in a
hACE2
murine model |
Kiran Deshpande, Keith R. Lange, William B. Stone, Christine Yohn, Naomi Schlesinger, Leonid Kagan, Albert J. Auguste, Bonnie L. Firestein, Luigi Brunetti |
| 11 |
[GO] |
2023―Apr―11 |
Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID-19 |
Rodolfo Pedro Rothlin, Facundo Germán Pelorosso, Mariano Duarte, Liliana Nicolosi, Fernandez Criado Ignacio, María Victoria Salgado, Héctor Vetulli |
| 12 |
[GO] |
2022―Dez―20 |
Phase 1 study of safety, pharmacokinetics, and antiviral activity of
SARS-CoV
-2 neutralizing monoclonal antibody
ABBV-47D11
in patients with
COVID
-19 |
Mohamad Shebley, Stanley Wang, Izna Ali, Preethi Krishnan, Rakesh Tripathi, Joseph M. Reardon, John Cafardi, Galia Rahav, Yoseph Caraco, Jihad Slim, Fadi Al Akhrass, Mengjia Yu, Yiran Hu, Rosa De Abreu Ferreira, Negar N. Alami |
| 13 |
[GO] |
2022―Sep―01 |
Toward a big picture of COVID-19 |
Felix Tretter, Janet J. McIntyre-Mills, Gary R. Smith |
| 14 |
[GO] |
2022―Jul―15 |
A practical treatment for
COVID
-19 and the next pandemic |
Jahar Bhattacharya, Robert Booy, Arturo Casadevall, Charles Dela Cruz, David S. Fedson, Joe G. N. Garcia, Gary Grohmann, Ivan F. N. Hung, Jeffrey R. Jacobson, Lance C. Jennings, Lester Kobzik, Aleksandra Leligdowicz, James K. Liao, Jennifer H. Martin, Daniel M. Musher, Charles N. Serhan, Masato Tashiro |
| 15 |
[GO] |
2022―Apr―09 |
Nucleoside analog GS-441524: pharmacokinetics in different species, safety, and potential effectiveness against Covid-19 |
Henrik Berg Rasmussen, Ragnar Thomsen, Peter Riis Hansen |
| 16 |
[GO] |
2022―Feb―17 |
Chronic cerebral aspects of long COVID, post-stroke syndromes and similar states share their pathogenesis and perispinal etanercept treatment logic |
Ian Albert Clark |
| 17 |
[GO] |
2022―Feb―02 |
Systems analysis shows that thermodynamic physiological and pharmacological fundamentals drive COVID-19 and response to treatment |
Richard J. Head, Eugenie R. Lumbers, Bevyn Jarrott, Felix Tretter, Gary Smith, Kirsty G. Pringle, Saiful Islam, Jennifer H. Martin |
| 18 |
[GO] |
2022―Feb―02 |
The interacting physiology of COVID-19 and the renin-angiotensin-aldosterone system: Key agents for treatment |
Eugenie R. Lumbers, Richard Head, Gary R. Smith, Sarah J. Delforce, Bevyn Jarrott, Jennifer Martin, Kirsty G. Pringle |
| 19 |
[GO] |
2022―Feb―02 |
Critical insights to COVID-19 disease and potential treatments using a systems analysis approach that integrates physiology, pharmacology, and clinical pharmacology |
Jennifer H. Martin, Richard J. Head |
| 20 |
[GO] |
2021―Dez―30 |
Molnupiravir: A new candidate for COVID-19 treatment |
Fariba Pourkarim, Samira Pourtaghi-Anvarian, Haleh Rezaee |
| 21 |
[GO] |
2021―Okt―28 |
Did our pharmacological strategy for COVID-19 fail? |
Jennifer H. Martin, Michelle Baddeley, Richard Head |
| 22 |
[GO] |
2021―Okt―28 |
Statin withdrawal and treating COVID-19 patients |
David S. Fedson |
| 23 |
[GO] |
2021―Okt―10 |
Bioequivalence and food effect of a fixed-dose combination of macitentan and tadalafil: Adaptive design in the COVID-19 pandemic |
Dénes Csonka, Vladislav Fishman, Jaya Natarajan, Hans Stieltjes, Danielle Armas, Victor Dishy, Juan Jose Perez Ruixo |
| 24 |
[GO] |
2021―Jun―15 |
Carrageenan nasal spray may double the rate of recovery from coronavirus and influenza virus infections: Re-analysis of randomized trial data |
Harri Hemilä, Elizabeth Chalker |
| 25 |
[GO] |
2021―Jun―15 |
p-cymene impairs SARS-CoV-2 and Influenza A (H1N1) viral replication:
In silico
predicted interaction with SARS-CoV-2 nucleocapsid protein and H1N1 nucleoprotein |
Athanasios Panagiotopoulos, Melpomeni Tseliou, Ioannis Karakasiliotis, Danai-Maria Kotzampasi, Vangelis Daskalakis, Nikolaos Kesesidis, George Notas, Christos Lionis, Marilena Kampa, Stergios Pirintsos, George Sourvinos, Elias Castanas |
| 26 |
[GO] |
2021―Mrz―12 |
Hemoadsorption eliminates remdesivir from the circulation: Implications for the treatment of COVID-19 |
Paul Biever, Dawid L. Staudacher, Michaela J. Sommer, Hannah Triebel, Merja A. Neukamm, Christoph Bode, Alexander Supady, Achim Lother |
| 27 |
[GO] |
2021―Jan―15 |
Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview |
Haleh Rezaee, Fariba Pourkarim, Samira Pourtaghi-Anvarian, Taher Entezari-Maleki, Touraj Asvadi-Kermani, Masoud Nouri-Vaskeh |
| 28 |
[GO] |
2020―Dez―31 |
Therapeutic approaches against coronaviruses acute respiratory syndrome |
Camilla Servidio, Francesco Stellacci |
| 29 |
[GO] |
2020―Dez―25 |
Targeting host cell proteases as a potential treatment strategy to limit the spread of SARS-CoV-2 in the respiratory tract |
Ismail A. El-Shimy, Mahmoud M. A. Mohamed, Syed Shahzad Hasan, Muhammad A. Hadi |
| 30 |
[GO] |
2020―Okt―30 |
Nucleotide analogues as inhibitors of SARS-CoV Polymerase |
Jingyue Ju, Xiaoxu Li, Shiv Kumar, Steffen Jockusch, Minchen Chien, Chuanjuan Tao, Irina Morozova, Sergey Kalachikov, Robert N. Kirchdoerfer, James J. Russo |
| 31 |
[GO] |
2020―Okt―21 |
A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far? |
Amanj Kurdi, Nouf Abutheraa, Lina Akil, Brian Godman |
| 32 |
[GO] |
2020―Sep―28 |
Pharmacological hypothesis: TPC2 antagonist tetrandrine as a potential therapeutic agent for COVID-19 |
Paula M. Heister, Robin N. Poston |
| 33 |
[GO] |
2020―Jul―27 |
Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients |
Bruce M. Hendry, Nina Stafford, Ahran D. Arnold, Arvind Sangwaiya, Vijay Manglam, Stuart D. Rosen, Jayantha Arnold |
| 34 |
[GO] |
2020―Jul―13 |
The renin-angiotensin-aldosterone system: Role in pathogenesis and potential therapeutic target in COVID-19 |
Cássia L. Braga, Rodrigo P. Silva-Aguiar, Denise Battaglini, Diogo B. Peruchetti, Chiara Robba, Paolo Pelosi, Patricia R. M. Rocco, Celso Caruso-Neves, Pedro L. Silva |
| 35 |
[GO] |
2020―Jun―24 |
Buying time: Drug repurposing to treat the host in COVID-19H |
Jennifer H. Martin, Julian Clark, Richard Head |
